

CORRESPONDENCE


This department is for the publication of informal communications that are of interest because they are informative and stimulating, and for the discussion of controversial matters. The mandate of this JOURNAL is to disseminate information relating to leprosy in particular and also other mycobacterial diseases. Dissident comment or interpretation on published research is of course valid, but personality attacks on individuals would seem unnecessary. Political comments, valid or not, also are unwelcome. They might result in interference with the distribution of the JOURNAL and thus interfere with its prime purpose.

Decline of Leprosy in Mainland China

TO THE EDITOR:

On a visit to Mainland China in June of 1980, the following facts, which supplement the account previously given (Int. J. Lepr. 48 [1980] 71-73), became available. They were obtained during a week involving the presentation of six lectures and seminars to 150-200 medical school staff and leprosy workers, including a briefing by those chiefly responsible for the Kwangtung Leprosy Control program in South China. Addition-

al information was presented to me in subsequent discussions with leprosy control personnel on a four-day invitational visit to Beijing with the Chinese Academy of Medical Sciences (Chinese Journal of Dermatology). As was to be expected, leprosy work was not of primary concern when the new government was established in 1949. Acute diseases, notably smallpox, plague, and cholera, received prime attention. Prior leprosy work was, however, continued and

INCIDENCE NEW LEPROUS CASES: CANTON MUNICIPALITY

by the 1960's received increased attention and effort.

In a recent report on leprosy in China (Lepr. Rev. 51 [1980] 29-33), the late Dr. James Maxwell is credited with having estimated that there were two million cases of leprosy in China. However, in his textbook (*Leprosy, A Practical Textbook for use in China*, Shanghai, 1937, Chapter 1), he noted that if attention was directed to clearly evident leprosy, a reasonable estimate was probably about 300,000 cases. If one considered all cases, including early, not readily diagnosed instances, then the estimate might be one million cases. The estimate of one million cases was then, and continued to be, the usually given prevalent figure. Present workers in China say this was too high, perhaps thinking in terms of readily evident cases.

Pre-1950, it was generally held that Kwangtung Province, in the extreme south, had approximately 100,000 cases. The Kwangtung authorities agree that this was a reasonably correct estimate. Their estimate in 1980 was that there are now 40,000 instances. This is a significant decrease which is supported by the chart of the sequential annual incidence figures for 21 years. This decline in incidence is compatible with charts previously presented in this journal for other areas (Int. J. Lepr. 43

[1975] 145-148; 48 [1980] 71-73). It was indicated that a similar decline in leprosy has taken place in other provinces, notably Shantung, Kiangsi, and Fukien. In West China, leprosy work, which in China is generally the responsibility of the Provincial Health Services, has perhaps not been as effective as in these provinces. Attention is being paid to improve the overall efforts. It seems evident that persistent efforts are being made to control this disease and that there is, on the whole, a significant decline in incidence resulting from treatment abetted by improved and more uniform standards of living.

During the "Cultural Revolution" (1966-1976), there was much disruption in the medical work of the country but the leprosy workers managed to continue their efforts and the decline in leprosy incidence was unbroken. Perhaps the fear of leprosy and the opprobrium associated with the disease played a role in protecting the leprosy services.

—Olaf K. Skinsnes, M.D., Ph.D.

*University of Hawaii at Manoa
John A. Burns School of Medicine
Department of Pathology
Leahi Hospital
Honolulu, Hawaii 96816
U.S.A.*

Rifampin 1200 mg Once Monthly Together With Daily Lamprène® and Dapsone in Treatment of Refractory Patients with Lepromatous Leprosy

TO THE EDITOR:

We found the paper by J. Languillon, S. J. Yawalkar, and A. C. McDougall, published in the March 1979 issue of your journal¹ interesting because it revealed for the first time the practical value of a once-monthly 1200 mg single dose rifampin schedule in the treatment of patients with lepromatous leprosy. The once-monthly rifampin administration, besides being effective and economical, facilitates patient compliance even for beggar patients. We therefore conducted through A.M.G. (In-

dia) International a trial with a triple-drug regimen, including a once-monthly 1200 mg rifampin schedule, in our leprosy facility, whose patients go out into the public for begging. This communication incorporates the results of this trial.

After screening 2400 patients, refractory patients with long-standing lepromatous leprosy suffering from recurrent lepra (ENL) reactions and not improving on 100 mg daily dapsone monotherapy (problem cases), were selected for this trial. The evaluable trial population comprised 73 pa-